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Summary: The effect of varying concentrations (0 — 52 mg/1) of purified thyroxine binding globulin (TBG) on
the microencapsulated antibody method for free thyroxine was investigated. The results demonstrated that
the free thyroxine values were strongly influenced by the concentration of thyroxine binding globulin in the
samples. The standard curve could no longer be distinguished at a concentration of purified thyroxine binding
globulin of 52 mg/1.
In the clinical application, we observed that the values obtained using the microencapsulated antibody method
were significantly higher than the expected values in patients receiving triiodothyronine treatment after total
thyroidectomy (theoretically nil) and in patients with untreated primary hypothyroidism with negligible
thyroxine (less than 12.9 nmol/1). These false positive values are considered to be due to the methodological
problem mentioned above, i. e. the microcapsule membrane is not efficient and therefore must be improved.
Consequently, any data based on this method should be interpreted with caution.
Introduction common is the effect of abnormal albumin concen-
T . lt j , - . trations or non-esterified fatty acid and thyroxineIt is generally accepted that current free thyroxine , . «. i
 u r /c ii\ TU / i u/τ-τ^ \ j· · ι · · ι j · ι- · ι binding globulin (5,13). Thus far, only one paper has(FT4) radioimmunoassay kits routinely used in clinical , , . \ ' . - . , τ ,
, « ' . r· i r j·«· · · u revealed in part that the results obtained with mi-laboratones are most useful for differentiating be- , ^ « ,., , , .
 rr , ,
u i*u · j· -j ι j u -*u ^ - j j· croencapsulated antibody methods were affected bytween healthy individuals and those with thyroid dis- , J
 A , ' · , · · , . , , ,.j /-· ^\ AUU u j·«·"· -j ui · u 4.u circulating unsaturated thyroxine binding globulin
orders (1, 2). Although differing considerably in both /7\
theory and practice, several methods for assaying FT4
are available (3). However, a completely reliable In the present study, using the Liquisol FT4 kit, the
method is still lacking. During the past decade, nu- distortion of results by circulating unsaturated thy-
merous papers have been published on the results roxine binding globulin in the determination of FT4
obtained using these commercial methods (4—6). Un- was investigated. This resulted in an evaluation of the
fortunately, as with all clinical laboratory methods, clinical accuracy of the Liquisol FT4 kit, in the di-
these methods suffer from interferences. The most agnosis of severe primary hypothyroidism.
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Materials and Methods
Experimental procedures
Preparation of thyroxine binding globulin
Highly purified thyroxine binding globulin was prepared from
pooled human serum by affinity chromatography as previously
described (8). The technique employed was essentially that
described by Pensky & Marchall (9). [125I]Thyroxine was added
to the purified material and the mixture subjected to disc
electrophoresis. The single band of stained protein coincided
with the single peak of radioactivity. The thyroxine binding
globulin did not contain any thyroxine (T4) after purification.
Assay procedures
The assay for FT4 using the Liquisol FT4 kit (Damon Diag-
nostics, USA) was performed in full accordance with the man-
ufacturer's instructions. Briefly, 25 μΐ of purified thyroxine
binding globulin (0, 13, 52 mg/1) were added to test tubes
containing 500 μΐ microcapsule suspension, which contained
anti-T4 combined with [125I]thyroxine. Twenty-five μΐ of each
standard (0, 1.94, 4.90, 14.2, 25.8, 40.0 and 64.5 pmol/1) were
pipetted into correspondingly labelled tubes and each tube was
vortexed for 4 seconds. The tubes were subsequently incubated
in a water bath at 37 °C for 2 hours. After one hour, all the
tubes were vortexed for a further 4 seconds and then returned
to the incubator. After incubation, 1 ml of wash solution (poly-
ethylenimine) was added to each tube, which was then vortexed
for a further 4 seconds. The tubes were incubated at room
temperature for 20 minutes, centrifuged at 1400 g for 10 min-
utes, then decanted. The microcapsules were counted in a
gamma counter for 1 minute. In the range 5.16 — 58.1 pmol/1,
the intra-assay coefficient of variation was 7.2 — 8.5%. In the
range 12.9 — 38.7 pmol/1, the inter-assay coefficient of variation
was 14.7 — 15.9%. FT4 was also measured using the Amerlex
kit (Amersham, U. K.); triiodothyronine, thyroxine, thyrotro-
pin, thyroglobulin and thyroxine binding globulin were meas-
ured with the EIKEN kit (EIKEN ICL, Japan), and T3 uptake
(T3U) was measured with the Dainabot kit (Dainabot, Japan).
The accuracy of these kits and the analytical procedures for
measurement of these hormones have previously been described
in detail (7). All samples were measured simultaneously in order
to avoid inter-assay variations. The results are expressed as the
mean ± standard deviation (SD).
Subjects
Thyroid function studies were performed on 156 normal adult
subjects, 106 pregnant women (30 subjects, 0 — 10 weeks; 22
subjects, 11-20 weeks; 24 subjects, 21 —30 weeks; 30 subjects,
31—40 weeks), 26 hyperthyroid patients and 29 primary hy-
pothyroid patients with detectable thyroxine (12.9 — 51.6
nmol/1). In addition, 16 patients with severe primary hypothy-
roidism with negligible thyroxine (less than 12.9 nmol/1) and
17 patients receiving triiodothyronine treatment after total thy-
roidectomy (thyroxine less than 12.9 nmol/1) were studied. Sera
were aliquoted and stored at —20 °C until the assay.
Results
The effect of different concentrations (0 — 52 mg/1) of
purified thyroxine binding globulin on the microen-
capsulated antibody method is shown in figure 1.
Four test tubes were prepared, each containing 500
μΐ of microcapsule suspension. To the first was added
25 μΐ of serum containing no thyroxine binding glob-
ulin; to the second, 25 μΐ of serum containing 13 mg/1
of purified thyroxine binding globulin; and to the
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Fig. 1. Effect of thyroxine binding globulin on the microen-
capsulated FT4 determination method.
third, 25 μΐ of serum containing 52 mg/1 of purified
thyroxine binding globulin. The results demonstrated
that the FT4 values, determined by Liquisol FT4, were
strongly influenced by the concentration of thyroxine
binding globulin in the samples. When the thyroxine
binding globulin concentration was increased,
[125I]thyroxine was extracted from the microcapsules.
Due to the leakage of [125I]thyroxine from the micro-
capsules, the standard curve can no longer be distin-
guished at a concentration of thyroxine binding glob-
ulin of 52 mg/1 (fig. 1).
A further examination of the Liquisol kit was under-
taken as a clinical study. Table 1 shows the circulating
FT4 levels determined by the Amerlex kit and Liquisol
kit in healthy normal subjects, pregnant women, pa-
tients with hyperthyroidism, and with primary hy-
pothyroidism with detectable thyroxine. As shown in
the table, the values obtained using the Liquisol kit
were always higher (P < 0.001) than those from the
Tab. 1. Concentrations (mean + SD) of serum FT4 determined
with the Amerlex kit and the Liquisol kit in normal
subjects, patients with hyperthyroidism, hypothyroid-
ism and pregnant women.
Subjects Amerlex kit Liquisol kit
Normal subjects
Hyperthyroidism
Hypothyroidism
Pregnant women
0-10 weeks
11-20 weeks
21-30 weeks
31-40 weeks
156
26
29
106
30
22
24
30
15.5 + 3.2
60.0 + 18.2
2.97 ± 2.71
25.3 + 5.9
20.6 ± 3.7
14.2 + 4.1
12.3 + 2.7
21.9 ± 4.9 **
72.5 4- 20.4 **
8.26 ± 3.35**
30.4 ± 7.1 **
27.1 + 8.1 **
23.2 + 7.0 **
22.7 + 5.8 **
Significance (by paired t test) of difference between Amerlex
kit and Liquisol kit
** p < 0.001
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Amerlex kit. Remarkably, the FT4 levels in late preg-
nancy (21—30 weeks and 31—40 weeks), when the
serum thyroxine binding globulin level increases, were
still higher than those of non-pregnant subjects (tab.
1), in contrast to the Amerlex FT4 kit which showed
lower levels than normal. As partly reported previ-
ously (7), the values obtained with the Liquisol kit
gave erroneously positive results in patients undergo-
ing triiodothyronine treatment after total thyroidec-
tomy (theoretically zero), or with severe primary hy-
pothyroidism (tab. 2, 3). In contrast, the values ob-
tained with the Amerlex kit were always zero.
Tab. 2. Concentrations of circulating thyroid hormones, triiodthyronine (T3), thyroxine (T4), T3 uptake (T3U), thyroxine binding
globulin (TBG) and thyrotropin (TSH) in patients with triiodothyronine treatment after total thyroidectomy.
Case No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Mean ±
Age
46
33
61
50
49
32
45
49
60
32
25
43
31
22
58
49
32
SD
Sex
g
$
$
c?
<j
<J
$
$
?
δ$$
c???
<J
c?
Normal range
T3
nmol/1
7.44
2.96
4.25
4.37
1.97
4.40
3.36
4.20
5.59
4.74
5.22
3.42
6.39
2.43
2.88
2.45
1.96
4.00 ±1.56
1.23-2.93
T4
nmol/1
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
59-142
TSH
mU/1
<0.1
4.18
2.22
1.42
3.14
1.52
2.28
1.32
0.25
1.33
1.22
1.44
«3.1
4.23
2.51
3.82
3.70
2.31 ±1.24
0.25-6.00
T3U
%
23.8
24.6
20.4
32.7
27.4
27.3
20.8
24.5
23.6
28.0
22.1
24.6
24.5
25.3
25.3
18.7
28.8
24.9 ±3 .4
24-37
TBG
mg/1
26.2
18.8
26.4
17.8
18.0
17.0
26.5
21.3
20.4
16.7
20.9
20.2
20.0
20.1
21.1
32.4
16.3
20.6 ±4.2
12-30
FT4
Liquisol kit
pmol/1
5.29
3.74
3.10
2.71
3.48
5.55
3.48
3.48
2.97
3.48
3.35
3.23
2.97
2.97
3.48
3.48
3.74
3.43 ±60
10.3-31.0
FT4
Amerlex kit
pmol/1
n.d.*
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
9.0-27.1
* n. d. = not detectable
The sensitivity of FT4 determination with the Amerlex kit is 1.94 pmol/1, and the sensitivity of the thyroxine determination is
12.9 nmol/1.
Tab. 3. Concentrations of circulating thyroid hormones, triiodothyronine (T3), thyroxine (T4), T3 uptake (T3U), thyroxine binding
globulin (TBG) and thyrotropin (TSH) in patients with severe primary hypothyroidism (thyroxine less than 12.9 nmol/1).
A
V
Case No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Mean ± SD
Age
63
72
31
32
51
49
49
53
43
45
60
42
50
42
42
45
Sex
c?$
£
c?
<j>$
2
9
δ$$>§$9$
δ
Normal range
Τ3
nmol/1
0.57
1.46
0.51
0.35
0.52
0.43
0.75
0.72
0.86
0.68
0.42
0.88
1.02
0.77
0.52
1.43
0.74 ±0.33
1.23-2.93
T4
nmol/1
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
•<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
<12.9
59-142
TSH
mU/1
120
104
240 <
240 <
78
28
81
96
240 <
240
171
125
79
101
99
70
132 ±71
0.25-6.00
T3U
%
24.6
23.1
26.2
25.6
20.0
21.8
19.8
24.2
20.4
23.0
29.4
21.8
20,3
33.6
21.4
26.7
23.9 ±3.8
24-37
TBG
mg/1
27.0
31.0
24.8
18.6
30.4
28.0
34.9
28.1
30.2
25.2
23.5
23.9
35.9
25.2
24.0
20.8
27.0 ±4.7
12-30
FT4
Liquisol kit
pmol/1
5.29
5.81
5.29
3.48
4.13
4.77
4.13
5.29
5.16
4.90
4.52
4.77
4.90
3.87
6.71
5.55
4.91 ±0.80
10.3-31.0
FT4
Amerlex kit
pmol/1
n.d.*
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
9.6-27.1
* n. d. = not detectable
The sensitivity of FT4 determination with the Amerlex kit is 1.94 pmol/1, and the sensitivity of the thyroxine determination is
12.9 nmol/1.
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Discussion
Numerous commercial methods are now available for
the measurement of FT4. Some claim that an accurate,
precise assay of FT4 provides the single best assess-
ment of thyroid function (10, 11). Unfortunately, as
with all clinical laboratory methods, FT4 methods
suffer from interferences. The most common is the
effect of abnormal albumin concentrations (12, 13) or
non-esterified fatty acids (14, 15). Since each FT4
method behaves uniquely, each should be independ-
ently viewed with respect to interference. Common
interferences (albumin effect, non-esterified fatty acid
effect) have been thoroughly studied, but the effect
of unsaturated thyroxine binding globulin has not yet
been investigated, although it has been suspected that
the performance of DPC kits (Diagnostic Products
Corp., USA) is dependent on the concentration of
thyroxine binding globulin in serum (16).
As shown in figure 1, the addition increasing amounts
of purified thyroxine binding globulin to a test tube
containing microcapsule suspension strongly affected
the accuracy of the results. We found that in the
presence of rather high amounts of thyroxine binding
globulin, [125I]thyroxine leaked through the membrane
into the medium, thereby giving a falsely elevated free
thyroxine result. Our finding indicates that further
improvements in the microcapsule membrane are nec-
essary for successful FT4 determination.
So far, little attention has been given to evaluation of
RIA methods for FT4 in patients with unsaturated
thyroxine binding globulin. The values obtained using
the Liquisol kit were significantly higher than the
expected values in patients with untreated primary
hypothyroidism with negligible thyroxine (tabs. 2, 3).
Melmed et al. (3) also reported erroneously high FT4
levels in patients with primary hypothyroidism using
the Liquisol kit. However, at that time, they did not
investigate the reason for these high levels.
Theoretically, FT4 levels in patients receiving triio-
dothyronine treatment after total thyroidectomy
should be nil. The reason for these false positive values
may lie in a methodological problem of the Liquisol
kit, which relies on FT4 moving through the micro-
capsule membrane. The possibility that the Liquisol
kit was not properly calibrated to zero, was disproved,
since it was shown that the zero serum of the Liquisol
FT4 kit was undetectable by Amerlex FT4 radioim-
munoassay.
In 1983, we put forward the hypothesis that the ar-
tificially high results obtained with the Liquisol kit
are due to the leakage of 125I from the microcapsule
(7). This hypothesis has been validated by the exper-
iment described in this paper. To avoid erroneous
interpretations, we would therefore advise caution,
especially when the results obtained with the Liquisol
kit are used as a test for patients with primary hy-
pothyroidism, since in these cases the thyroxine bind-
ing globulin concentration is usually increased (17).
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